

Status: Currently Official on 13-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: USP Monographs
 DocId: GUID-28F6A917-A21C-4749-ACD0-6945D1F45859_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M2432_02_01
 DOI Ref: q7tz4

© 2025 USPC
 Do not distribute

Aripiprazole Orally Disintegrating Tablets

DEFINITION

Aripiprazole Orally Disintegrating Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of aripiprazole ($C_{23}H_{27}Cl_2N_3O_2$).

IDENTIFICATION

Change to read:

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), *Infrared Spectroscopy: 197A*▲ (CN 1-MAY-2020)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Solution A: 2.84 g/L of sodium sulfate in water

Buffer: 3.48 g/L of dibasic potassium phosphate adjusted with phosphoric acid to a pH of 8.2

Mobile phase: Acetonitrile and *Buffer* (50:50)

Diluent A: Acetonitrile, methanol, *Solution A*, and glacial acetic acid (33:11:56:1)

Diluent B: Acetonitrile and 0.1 M hydrochloric acid (20:80)

System suitability solution: 0.01 mg/mL each of [USP Aripiprazole RS](#) and [USP Aripiprazole Related Compound G RS](#) in *Diluent A*. Sonication and shaking may be used to aid in dissolution.

Standard solution: 0.25 mg/mL of [USP Aripiprazole RS](#) in *Diluent B*. Sonication may be used to aid in dissolution.

Sample solution: Nominally 0.2–0.3 mg/mL of aripiprazole from NLT 5 Orally Disintegrating Tablets prepared as follows. Transfer NLT 5 Orally Disintegrating Tablets to a suitable volumetric flask and dilute with *Diluent B* to NMT 75% of the final flask volume. Sonicate for 5 min and shake for 15 min. Dilute with *Diluent B* to volume. Pass the resulting solution through a suitable filter and use the filtrate.

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

Mode: LC

Detector: UV 252 nm

Column: 4.6-mm × 10-cm; 3.5-μm packing L1

Flow rate: 1 mL/min

Injection volume: 10 μL

Run time: NLT 1.4 times the retention time of aripiprazole

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—The relative retention times of aripiprazole related compound G and aripiprazole are 0.74 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 3.0 between aripiprazole related compound G and aripiprazole, *System suitability solution*

Tailing factor: NMT 1.5, *Standard solution*

Relative standard deviation: NMT 1.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of aripiprazole ($C_{23}H_{27}Cl_2N_3O_2$) in the portion of Orally Disintegrating Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Aripiprazole RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of aripiprazole in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

- [DISINTEGRATION \(701\)](#): NMT 60 s
- [DISSOLUTION \(711\)](#)

Medium: pH 4.0 sodium acetate trihydrate buffer (3.0 g/L of sodium acetate prepared as follows. Transfer a suitable quantity of sodium acetate to a suitable container containing 90% of the final container volume of water. Adjust with glacial acetic acid to a pH of 4.0. Add water to the final volume.), degassed; 1000 mL

Apparatus 2: 75 rpm

Time: 30 min

Mobile phase: Acetonitrile and 0.025 M hydrochloric acid (40:60)

Standard solution: (L/1000) mg/mL of [USP Aripiprazole RS](#) in *Mobile phase* where L is the label claim in mg/Tablet

Sample solution: Pass a portion of the solution under test through a suitable filter, discarding the first few mL.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 225 nm

Column: 4.6-mm × 15-cm; 5-μm packing L1

Flow rate: 1 mL/min

Injection volume: 20 μL

Run time: NLT 1.5 times the retention time of aripiprazole

System suitability

Sample: *Standard solution*

Suitability requirements

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of aripiprazole ($C_{23}H_{27}Cl_2N_3O_2$) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times (1/L) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Aripiprazole RS](#) in the *Standard solution* (mg/mL)

V = volume of *Medium*, 1000 mL

L = label claim (mg/Tablet)

Tolerances: NLT 80% (Q) of the labeled amount of aripiprazole ($C_{23}H_{27}Cl_2N_3O_2$) is dissolved.

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

IMPURITIES**• ORGANIC IMPURITIES**

Solution A: Water and trifluoroacetic acid (100:0.05)

Solution B: Acetonitrile and trifluoroacetic acid (100:0.05)

Solution C: 2.84 g/L of sodium sulfate in water

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	90	10
20	70	30
40	42	58
50	10	90
55	10	90